Clinical trials
Myeloma clinical trials
Below are recruiting myeloma clinical trials, each written for real people, not researchers. We’re tracking 572 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06055894Recruiting
Plant-based diet and supplements for smoldering myeloma or MGUS
This study tests whether a plant-based diet and certain supplements can help people with smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS). Participants will learn to cook plant-based recipes and track their meals using a phone app.
Basking Ridge, New JerseyAges 18 years+ - NCT06115135RecruitingPhase 2
Venetoclax with isatuximab and dexamethasone for myeloma
This trial tests a combination of three drugs (venetoclax, isatuximab, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to earlier treatments. It is for patients whose cancer cells have a specific genetic change, called t(11;14).
West Hollywood, CaliforniaAges Any age - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06140524RecruitingPhase 2
Study of Linvoseltamab for high-risk MGUS or smoldering myeloma
This trial tests if linvoseltamab can remove abnormal plasma cells that might turn into multiple myeloma. It is for patients with high-risk MGUS (a precancerous condition) or non-high-risk smoldering myeloma who have not yet developed active myeloma.
Baltimore, MarylandAges 18 years+ - NCT06140966RecruitingPhase 2
Daratumumab and Carfilzomib combo for high-risk multiple myeloma
This trial tests a combination of the drugs daratumumab, carfilzomib, lenalidomide, and dexamethasone given before and after a stem cell transplant for people with ultra high-risk multiple myeloma. The goal is to see if this regimen is safe and more effective than standard treatments.
Wuhan, HubeiAges 18–70 - NCT06158412RecruitingPhase 2
ATRA plus KPD for relapsed or refractory multiple myeloma
This trial tests a combination of all-trans retinoic acid (a form of vitamin A) with a chemotherapy regimen called KPD for patients whose multiple myeloma has come back or is not responding to standard treatments. The goal is to see if this combination can help control the disease.
Xiamen, FujianAges 18 years+ - NCT06183489RecruitingPhase 2
Elranatamab for high-risk smoldering multiple myeloma
This trial tests a new drug called Elranatamab for people with a high-risk form of smoldering multiple myeloma (SMM). The goal is to see if the drug can prevent or delay the progression to active multiple myeloma.
HelsinkiAges 18 years+ - NCT06212323Recruiting
Monitoring high-risk smoldering myeloma over time
This trial watches people with a high-risk form of smoldering myeloma (an early, inactive stage of bone marrow cancer) to learn more about how it changes. It may help doctors know who needs treatment later.
Salt Lake City, UtahAges 18 years+ - NCT06433947RecruitingPhase 1
Testing an experimental drug OPN-6602 for advanced multiple myeloma
This trial tests an experimental oral drug called OPN-6602 for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose.
Gilbert, ArizonaAges 18 years+ - NCT06465316RecruitingPhase 1
Teclistamab plus iberdomide for relapsed multiple myeloma
This trial tests a combination of two drugs, teclistamab and iberdomide, for people with multiple myeloma that has come back or stopped responding to at least 4 prior treatments. The goal is to see if this combination can work when other options have failed.
Phoenix, ArizonaAges 18 years+ - NCT06518551RecruitingPhase 1/Phase 2
Elotuzumab, Iberdomide, and Dexamethasone after Ide-cel for multiple myeloma
This trial tests a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) for multiple myeloma that has come back after treatment with a type of CAR T-cell therapy called ide-cel. It aims to see if this new combination can help people who have already tried several other treatments.
Boston, MassachusettsAges 18 years+ - NCT06561854RecruitingPhase 3
Comparing multiple myeloma treatment with and without dexamethasone
This trial tests whether adding dexamethasone to an antibody-based combination therapy works better for multiple myeloma that has come back after previous treatments. If you have had 1 to 3 prior therapies and are eligible for one of two standard drug regimens, this study may help find the best approach for you.
ParisAges 18 years+ - NCT06572605RecruitingPhase 1/Phase 2
Radiation plus talquetamab for myeloma outside the bone
This trial tests combining radiation therapy with a targeted drug called talquetamab for multiple myeloma that has formed tumors outside the bone (extramedullary disease). It aims to see if this combination can shrink or control these tumors and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT07689058RecruitingPhase 2
CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
Rawalpindi, Punjab ProvinceAges 18 years+ - NCT07657312RecruitingPhase 2
Infliximab to prevent side effects during myeloma treatment
This trial tests if infliximab, a drug that calms the immune system, can prevent cytokine release syndrome (a serious side effect) when patients receive teclistamab or talquetamab for multiple myeloma that has returned or not responded to treatment.
Columbus, OhioAges 18 years+ - NCT06622005RecruitingPhase 1
Testing SX-682 with standard drugs for relapsed myeloma
This trial tests a new drug called SX-682 added to a standard three-drug combination (carfilzomib, daratumumab, dexamethasone) for people with multiple myeloma that has returned or stopped responding to earlier treatments. The goal is to see if adding SX-682 can help control the cancer better.
Buffalo, New YorkAges 18 years+ - NCT06644625Recruiting
CHAAMP study: MGUS screening for Black adults and relatives
This study screens for MGUS, a precursor to certain blood cancers, in people who are Black or African American, or who have a close relative with a plasma cell disorder. If MGUS is found, you may be invited to continue in the study to monitor your health.
Charlotte, North CarolinaAges 30 years+ - NCT06679101RecruitingPhase 3
Belantamab combination vs standard care for newly diagnosed multiple myeloma
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
Mobile, AlabamaAges 18 years+ - NCT06932562RecruitingPhase 3
Testing linvoseltamab vs standard care for myeloma patients not eligible for transplant
This trial compares a new drug called linvoseltamab to standard treatments for multiple myeloma. It is for people who cannot have a stem cell transplant and have not had extensive prior therapy.
AdelaideAges 18 years+ - NCT06971380RecruitingPhase 2
CAR-T therapy for multiple myeloma and amyloidosis
This trial tests a new CAR-T cell treatment (HBI0101) for people with multiple myeloma or light-chain amyloidosis that has come back or stopped responding to other treatments. The therapy uses your own immune cells to fight cancer, and the goal is to see if it can help control the disease.
JerusalemAges 18 years+ - NCT06974786RecruitingPhase 2
T-cell engager vs stem cell transplant for newly diagnosed myeloma
This trial compares two approaches after initial therapy for newly diagnosed multiple myeloma: a T-cell engager (elranatamab) versus a stem cell transplant. The goal is to see which provides better control of the disease, using sensitive MRD testing to guide further treatment.
Birmingham, AlabamaAges 19 years+ - NCT07093554RecruitingPhase 1
Talquetamab and Cilta-cel for relapsed multiple myeloma
This trial tests giving an immunotherapy drug (talquetamab) before CAR T-cell therapy (cilta-cel) to see if it helps people with multiple myeloma that has come back or stopped responding to other treatments.
Milwaukee, WisconsinAges 18 years+ - NCT07107529RecruitingPhase 2
Study of daratumumab with teclistamab or talquetamab for frail patients with newly diagnosed multiple myeloma
This trial tests a combination of drugs—daratumumab plus either teclistamab or talquetamab—for people who have just been diagnosed with multiple myeloma and are considered frail. The goal is to see if this treatment is safe and effective for those who may not be strong enough for standard therapies.
Ascoli PicenoAges 18 years+ - NCT07181941RecruitingPhase 1/Phase 2
Testing lower doses of linvoseltamab for multiple myeloma
This trial tests if a lower dose of linvoseltamab can still work well for people with multiple myeloma that has come back or not responded to treatment. It aims to reduce side effects while keeping the cancer under control.
Seattle, WashingtonAges 18 years+
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myeloma?
- Yes. Clin2 currently lists 572 recruiting myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.